J
Jean-Jacques Body
Researcher at Université libre de Bruxelles
Publications - 397
Citations - 21506
Jean-Jacques Body is an academic researcher from Université libre de Bruxelles. The author has contributed to research in topics: Breast cancer & Zoledronic acid. The author has an hindex of 70, co-authored 384 publications receiving 19608 citations. Previous affiliations of Jean-Jacques Body include The Breast Cancer Research Foundation & University of California, San Francisco.
Papers
More filters
Journal ArticleDOI
Hypercalcemia of malignancy.
TL;DR: The use of bisphosphonates in placebo-controlled trials has shown that the incidence of hypercalcemic episodes is reduced by more than one half and antibodies against parathyroid hormone-related protein could be useful for that matter in selected patients who are not in the terminal stage of their disease.
Journal ArticleDOI
Dose/response study of aminohydroxypropylidene bisphosphonate in tumor-associated hypercalcemia
TL;DR: Fasting urinary calcium levels are probably the most reliable and easily measured parameter to monitor AHPrBP's inhibition of bone resorption in normocalcemic patients, and lies between 0.25 and 1.5 mg/kg per day.
Journal ArticleDOI
Bisphosphonates antagonise bone growth factors' effects on human breast cancer cells survival.
TL;DR: It is reported that bisphosphonates antagonised the stimulatory effects of growth factors on human breast cancer cell survival and reduced their protective effects against apoptotic cell death in vitro under serum-free conditions.
Journal ArticleDOI
Systematic review and meta-analysis on the proportion of patients with breast cancer who develop bone metastases.
Jean-Jacques Body,Geoffrey Quinn,Geoffrey Quinn,Susan Talbot,Emma Booth,Gaston Demonty,Aliki Taylor,Justyna Amelio +7 more
TL;DR: A systematic literature review was conducted to quantify populations of patients with primary breast cancer in whom bone metastases were detected at study start or during follow-up, and to inform on the global burden ofBone metastases by defining patient populations that are at risk of developing bone metastase.
Journal ArticleDOI
Production and regulation of interleukin-11 by breast cancer cells.
TL;DR: The data suggest that Il-11, together with Il-6, contributes to the high bone destructive capacity of MDA-MB-231 cells and could play a role in breast cancer-induced osteolysis.